These findings highlight the potential benefit of addressing both retinal hypoxia and venous hypertension through the combined use of HOT and anti-VEGF therapy in selected cases of mixed retinal vascular occlusion. This evidence concerns the gene VEGFA and retinal vascular occlusion.